

**Steven Grinspoon**



Dr. Steven Grinspoon is a Professor of Medicine, Harvard Medical School, Chief of the MGH Metabolism Unit, and Director of the Nutrition Obesity Research Center at Harvard. He has had a long-standing interest in the metabolic and immune complications of HIV disease. He chaired the American Heart Association State of the Science Conference on Cardiovascular Disease in HIV infected patients. His work has suggested significant cardiovascular disease in people with HIV (PWH) and highlighted the relative contributions of traditional risk factors, including diabetes and excess visceral fat accumulation, and of nontraditional risk factors, including inflammation and immune activation, using novel PET and CT techniques linking arterial inflammation to high risk vulnerable plaque. In this regard, he is a

co-leader of the 7700 participant, global NIH-funded REPRIEVE study to prevent cardiovascular disease in HIV. In addition, he has shown efficacy of strategies to improve ectopic adipose tissue, leading the development of an FDA approved strategy for visceral fat reduction. For his work, Dr. Grinspoon was awarded the 2016 Aurbach Laureate award in translational research from the Endocrine Society. Dr. Grinspoon is a member of the American Society of Clinical Investigation and the Association of American Physicians, honoring his achievements.

**Rohan Wijesurendra**



Rohan studied medicine at Cambridge University, before moving to Oxford for postgraduate medical training, research towards a PhD/DPhil, and completion of higher specialist training in cardiology. He is now a Senior Clinical Research Fellow in the Nuffield Department of Population Health at the University of Oxford and also works as an Honorary Consultant Cardiologist and Electrophysiologist at Oxford University Hospitals NHS Foundation Trust. His research combines large-scale trials in cardiovascular disease with more mechanistic clinical studies; he has particular interests in atrial fibrillation and cardiometabolic risk factor modification. He continues to undertake a wide gamut of clinical work in cardiac rhythm management, including diagnostic electrophysiology, simple and complex ablation,

and device implantation and extraction. In addition to his research and clinical commitments, he regularly undertakes undergraduate and postgraduate teaching, and is a Stipendiary Lecturer in Clinical Medicine at St John's College, Oxford.

**Jane Armitage**



Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine.

Since joining CTSU in 1990 Jane has co-ordinated and been chief investigator for a series of large-scale randomised clinical trials in cardiovascular disease including the 20,000 participant MRC/BHF Heart Protection Study, the 12,000 patient SEARCH and 25,000 HPS2-THRIVE study, which are trials of lipid modification in people with or at risk of vascular disease. In addition she is Chief Investigator for the BHF-supported ASCEND trial of aspirin and fish oils involving 15,000 people with diabetes. She collaborates with other epidemiologists and statisticians in NDPH on a variety of genetic and other risk factor studies based on the trial cohorts. She has

a particular interest in the safety of statins. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic diseases including osteoporosis.

**Christian Hassager**



Christian Hassager is a cardiologist and former (2004-2018) director of a specialized cardiology intensive care unit at the University Hospital Rigshospitalet in Copenhagen, Denmark, and now Professor in this field at Copenhagen University. He is also associated professor in Cardiology at the University of Southern Denmark. He is chair of the Danish Heart Association and active board member of the European Society of Cardiology (ESC). He is past-president of the Danish Resuscitation Council as well as the Association for Acute Cardiovascular Care (ACVC) under ESC. He is former president of the Danish Society of Cardiology.

He is co-author of more than 600 scientific papers. His current major clinical research interest regards cardiogenic shock and post resuscitation care after cardiac arrest.

## Louise Bowman



Louise Bowman is Professor of Medicine and Clinical Trials at the Clinical Trial Service Unit of the University of Oxford. Her specialist clinical background is in Diabetes and Endocrinology. She has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics. She is Chief Investigator for the ORION-4 trial which will assess the effects of inclisiran on clinical outcomes among 15,000 people with atherosclerotic cardiovascular disease, and for the AMALFI trial, which will assess the value of screening for undiagnosed atrial fibrillation in 5000 high-risk individuals.

Through her work on large-scale trials in cardiovascular disease, she has developed a specialist interest in Clinical Trials Methodology and is Co-course Director of the Nuffield Department of Population Health MSc in Clinical Trials. Her focus is on the development, application and widespread promotion of methods to enhance the design and conduct of trials to ensure high quality outputs and reliable results at low cost.

## Toral Gathani



Toral Gathani is a Senior Clinical Research Fellow in the Cancer Epidemiology Unit of the Nuffield Department of Population Health, University of Oxford, Consultant Breast Surgeon at Oxford University Hospitals NHS Foundation Trust and Senior Research Fellow at Green Templeton College.

She studied Medicine at the University of St Andrews and Guy's and St Thomas' Medical School graduating in 1999 with Honours. She undertook her surgical training in London and at the Nottingham Breast Institute. Toral was a research fellow in the Cancer Epidemiology Unit at Oxford in 2003-2006 where she undertook the research for her MD thesis.


She is the Co-Chief Investigator of the AgeX Trial assessing the benefits and risks of extending the age range for routine screening invitations. She is also the Principal Investigator for a Cancer Research UK funded project on the Associations of Ethnicity and Breast Cancer. The Royal College of Surgeons of England awarded her a prestigious Hunterian Lecture, and courtesy title of Hunterian Professor 2022, for her work in this area. Nationally, she is a member of the Clinical Advisory Panel for Cancer Research UK, the Academic and Research Committee for the Association of Breast Surgery, and the Audit Advisory Committee for the National Audit of Primary Breast Cancer.

## Kaitlin Mayne



Kaitlin is a Clinical Research Fellow with the Renal Studies Group within CTSU (Nuffield Department of Population Health, University of Oxford). She works on the EMPA-KIDNEY trial and led analysis of the trial's bioimpedance substudy as part of her PhD studying the effect of empagliflozin on fluid overload in chronic kidney disease. Before her current Clinical Research Fellow role, Kaitlin was a Nephrology trainee based in Glasgow. She will return to this previous post later in 2024 to complete clinical Nephrology training and hopes to continue to pursue academic training alongside.

## Nikita Agrawal



Nikita Agrawal is a Clinical Research Fellow with the Renal Studies Group within CTSU (Nuffield Department of Population Health, University of Oxford). She joined the group having completed her Renal and General Medicine registrar speciality training in the North-East North-Central London deanery, with a special interest in transplantation. She works on EMPA-KIDNEY post-trial follow-up as well as the long-term follow-up of the 3C trial in kidney transplantation, as part of her Oxford DM degree.

## Parminder Judge



Parminder K Judge is a Senior Clinical Research Fellow based in the Renal Studies Group at the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and an Honorary Consultant Nephrologist in the Oxford Kidney Unit.

In 2013, she took time out of her nephrology training and joined CTSU to work on clinical trials, primarily the UK HARP-III trial which compared the effects of sacubitril/valsartan with irbesartan in 400 people with chronic kidney disease. The trial formed the basis of her PhD thesis. After completing her nephrology specialty training, Parminder returned to CTSU in 2020 to work on clinical trials in nephrology and cardiovascular disease, including the EMPA-KIDNEY trial.

She is a co-PI for the EASi-KIDNEY trial testing aldosterone synthase inhibition in people with chronic kidney disease. Parminder's other area of interest is the epidemiology of chronic kidney disease in South Asians.

## Isla Mackenzie



Isla Mackenzie is Professor of Cardiovascular Medicine and Associate Dean for Research in the School of Medicine at the University of Dundee. She completed specialist training in Clinical Pharmacology and Therapeutics and General Internal Medicine in Cambridge and has a PhD in Clinical Pharmacology from the University of Cambridge. She is an Honorary Consultant Physician at Ninewells Hospital, Dundee and contributes to the cardiovascular risk clinical service. She has led several clinical trials, many including decentralised elements. She leads a work package of the IMI Trials@Home project, optimising decentralised clinical trials in Europe, and represented Trials@Home on the NIHR Remote Methods of Trials Delivery Group. She is a member of the BHF Clinical Studies Committee. In 2018, she was awarded the Grahame-Smith Prize for Clinical Pharmacology by the British Pharmacological Society for outstanding contributions to research in clinical pharmacology.

## Axel Diederichsen



Axel Diederichsen is Professor in Cardiac Imaging at the Department of Cardiology, Odense University Hospital, Denmark. The vision of Axel's research is "more years without cardiovascular disease". He aims to improve methods to identify healthy people at increased cardiovascular risk, and to improve their outcomes at a reasonable cost. As PI and project manager, he leads several large randomised clinical trials including the Danish Cardiovascular Screening Trial, DANCAVAS 1 and 2. The focus of these studies is primarily prevention of coronary heart disease, but also stroke, aortic stenosis, dissection and rupture, peripheral artery disease, and mortality. The trials are running at several sites across Denmark and are conducted in close collaboration with a range of researchers and technicians. Other studies Axel leads are the Steno INTEN-CT study, the AVADEC trial of aortic calcification and the DANish COronary DEcalcification (DANCODE) trial.

## Christoph Wanner



Christoph Wanner is a Senior Professor of Medicine in the Department of Clinical Studies and Epidemiology, University Hospital of Würzburg and a Visiting Professor of Renal Medicine at the Nuffield Department of Population Health, Clinical Trial Service Unit, University of Oxford UK. His research is in the field of diabetic kidney disease, lipid disorders, and rare kidney diseases with a future focus on maintenance or restoration of kidney health. He has published more than 950 PubMed referenced scientific papers and articles (Hirsch Index Web of Science 109, Google Scholar 145). He has been PI of the 4D study and a steering committee member of the SHARP, the Empagliflozin studies and the FIND CKD study aiming to improve the management of cardiovascular and kidney disease progression and treatment of kidney failure by dialysis. Wanner's two landmark studies in this field have been published in 2005 (The 4D Study) and in 2015 & 2016 (EMPA-REG Outcome). In 2016 he received the highest awards from the European Renal Association (ERA) and the German Society of Nephrology. Dr. Wanner is currently President of the ERA, being in office June 2020-2024.